ViMRT
}  
 
Home   
< Docs   

 HBV mutation literature information.


  YSDD: a novel mutation in HBV DNA polymerase confers clinical resistance to lamivudine.
 PMID: 12823591       2003       Journal of viral hepatitis
Abstract: In addition, this new variant had the rtL180M mutation and a 12 base pair deletion in the pre-S1 region between nucleotides 43-54.
Abstract: In conclusion, the results indicate that, in addition to a Met --> Val and Met --> Ile change in YMDD, a Met --> Ser change at rt204 (YMDD --> YSDD) associated with the rtL180M change can also emerge during lamivudine treatment, which confers lamivudine resistance in vivo and in vitro, leading to virological breakthrough and ALT increases.
Abstract: Of the seven patients, six were HBeAg positive at baseline, and four had a double mutation consisting of rt


  Prevalence and characterization of lamivudine-resistant hepatitis B virus mutations in HIV-HBV co-infected individuals.
 PMID: 12853747       2003       AIDS (London, England)
Abstract: Unique mutations were detected in HBV polymerase, including rtV173L plus rtL180M plus rtM204V, which occurred in three patients.


  The hepatitis B virus polymerase mutation rtV173L is selected during lamivudine therapy and enhances viral replication in vitro.
 PMID: 14557667       2003       Journal of virology
Abstract: A second mutation, rtL180M, was previously reported to partially restore replication fitness as well as to augment drug resistance in vitro.
Abstract: In these patients, rtV173L was invariably found as a third mutation in conjunction with rtL180M and rtM204V.


  Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.
 PMID: 14642631       2003       Journal of hepatology
Abstract: RESULTS: Sequence analyses of the HBV polymerase gene revealed a sequential selection of lamivudine resistance mutations L180M+M204V, followed by a reversion to wild-type, and subsequently the selection of a novel adefovir resistance mutation N236T.


  Monitoring the emergence of hepatitis B virus polymerase gene variants during lamivudine therapy in human immunodeficiency virus coinfected patients: performance of CLIP sequencing and line probe assay.
 PMID: 14760897       2003       Antiviral therapy
Abstract: Interestingly, TRUGENE sequencing identified on late samples from three patients a variant carrying rtV173L plus rtL180M plus M204V mutations, having the in vitro characteristics of 'vaccine escape' mutants.


  Lamivudine therapy of chronic hepatitis B in three groups of patients: non transplanted patients, liver recipients, and kidney recipients.
 PMID: 11938042       2002       Gastroenterologie clinique et biologique
Abstract: After the development of lamivudine resistance, mutations rtM204V and rtL180M were detected in all studied patients, mutation rtM207I in one, with similar results from traditional nucleotide sequencing and a commercial line probe assay.


  "Restoration of replication phenotype of lamivudine-resistant hepatitis B virus mutants by compensatory changes in the ""fingers"" subdomain of the viral polymerase selected as a consequence of mutations in the overlapping S gene."
 PMID: 12167344       2002       Virology
Abstract: The LMV-resistant HBV mutants rtM204I and rtL180M/M204V produced substantially weaker HBV DNA replicative intermediate signals by Southern blot analysis and less total intracellular HBV DNA by real-time PCR compared to wild-type virus.
Abstract: The two most common LMV-resistant mutants produce changes in the viral polymerase protein (rt) of rtM204I and rtL180M/M204V (previously rtM550I and rtL526M/


  Identification of a new variant in the YMDD motif of the hepatitis B virus polymerase gene selected during lamivudine therapy.
 PMID: 12171302       2002       Journal of medical microbiology
Abstract: The mutation was followed by a leucine to methionine change at position 180 (rtL180M).


  Hepatitis B virus resistance to lamivudine and its clinical implications.
 PMID: 12448687       2002       Antiviral chemistry & chemotherapy
Abstract: These mutations are found at codon (or AA) rtL180M and rtM204V/I in the reverse transcriptase (RT) domain of the HBV polymerase for all genotypes according to a new standardized RT domain numbering system.


  Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region.
 PMID: 11230757       2001       Hepatology (Baltimore, Md.)
Abstract: In this proposal, the HBV rt domain starts with the highly conserved EDWGPCDEHG motif, contains 344 amino acids, and the lamivudine-related resistance mutations are found at amino acid rtL180M (previously amino acid 528, 526, 515, or 525) and rtM204V/I (previously 552, 550, 539, or 549).



Browser Board

 Co-occurred Entities




   Filtrator